Last Updated: May 3, 2026

DHIVY Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Dhivy, and what generic alternatives are available?

Dhivy is a drug marketed by Avion Pharms and is included in one NDA. There are three patents protecting this drug.

This drug has seven patent family members in six countries.

The generic ingredient in DHIVY is carbidopa; levodopa. There are eighteen drug master file entries for this compound. Thirty-eight suppliers are listed for this compound. Additional details are available on the carbidopa; levodopa profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Dhivy

A generic version of DHIVY was approved as carbidopa; levodopa by DR REDDYS LABS SA on August 28th, 1992.

  Start Trial

AI Deep Research
Questions you can ask:
  • What is the 5 year forecast for DHIVY?
  • What are the global sales for DHIVY?
  • What is Average Wholesale Price for DHIVY?
Summary for DHIVY
International Patents:7
US Patents:3
Applicants:1
NDAs:1

US Patents and Regulatory Information for DHIVY

DHIVY is protected by five US patents.

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Avion Pharms DHIVY carbidopa; levodopa TABLET;ORAL 214869-001 Nov 12, 2021 RX Yes Yes ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Avion Pharms DHIVY carbidopa; levodopa TABLET;ORAL 214869-001 Nov 12, 2021 RX Yes Yes ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Avion Pharms DHIVY carbidopa; levodopa TABLET;ORAL 214869-001 Nov 12, 2021 RX Yes Yes ⤷  Start Trial ⤷  Start Trial Y ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for DHIVY

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
3209302 2390502-9 Sweden ⤷  Start Trial PRODUCT NAME: FOSLEVODOPA/FOSCARBIDOPA; NAT. REG. NO/DATE: MTNR 62386 20220912; FIRST REG.: AT 141371 20220826
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.